BioTech Videos

Glioblastoma, ecDNA & Targeted Therapy - The Verhaak Lab at Yale School of Medicine

The Verhaak Lab at Yale School of Medicine presented research on extrachromosomal circular DNA (ecDNA) in glioblastoma, explaining how these small DNA loops differ from the linear chromosomes that normally house genetic material. The team showed that ecDNA enables tumor cells to rapidly adapt to hostile microenvironments, conferring resistance to radiation and chemotherapy. By profiling individual patient tumors with billions of data points, they pinpointed oncogenic drivers carried on ecDNA and translated those findings into functional experiments to validate drug targets. Lead researcher emphasized glioblastoma’s grim prognosis—grade‑four, median survival measured in months—and the toxicity of conventional chemotherapies that often force treatment discontinuation. He argued that targeted small‑molecule therapies could strike cancer cells while sparing healthy tissue, reducing side effects. If successful, these precision agents could move quickly through early‑phase trials, offering a rare therapeutic avenue for a disease that has seen little progress in four decades. The lab’s collaborative model, integrating neuro‑oncology, surgery, pathology and open‑science data sharing, underscores the broader need for interdisciplinary effort to tackle refractory brain tumors.